MA27003A1 - Pyridazinones servant d'inhibiteurs d'aldose-reductase. - Google Patents

Pyridazinones servant d'inhibiteurs d'aldose-reductase.

Info

Publication number
MA27003A1
MA27003A1 MA27314A MA27314A MA27003A1 MA 27003 A1 MA27003 A1 MA 27003A1 MA 27314 A MA27314 A MA 27314A MA 27314 A MA27314 A MA 27314A MA 27003 A1 MA27003 A1 MA 27003A1
Authority
MA
Morocco
Prior art keywords
present
inhibitors
diabetic
relates
diabetes
Prior art date
Application number
MA27314A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27003A1 publication Critical patent/MA27003A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATIONS DE PRIORIETES US 30 Mars 2001 60/280,051 Voir en annexe le titre de l'invention et le texte de l'abrégé Pyridazinones servant d'inhibiteurs d„aldose-réductase La présente invention concerne des dérivés de pyridazinone nouveaux, des compositions pharmaceutiques comprenant ces composés et des méthodes d'utilisation de ces composés et compositions pour inhiber l„aldose-réductase, abaisser les taux de sorbitol et, ainsi abaisser les taux de fructose et/ou traiter ou prévenir les complications du diabète telles que la neuropathie diabétique, la rétinopathie diabétique, la néphropathie diabétique, la myocardiopathie diabétique, la micro-angiopathie diabétique et la macroangiopathie diabétique chez des mammifères. La présente invention concerne également des méthodes pour assurer la cardio-protection de sujets ne souffrant pas de diabète. La présente invention concerne également des compositions pharmaceutiques et kits comprenant une association d'un inhibiteur d'aldose-réductase (ARI) de la présente invention et d'un inhibiteur de sorbitol-déshydrogénase, et des méthodes d'utilisation de ces compositions ou kits pour le traitement ou la prévention des complications précitées du diabète chez des mammifères. La présente invention concerne également d'autres associations avec les ARI de la présente invention, comprenant des associations avec des agonistes d'adénosine ; des inhibiteurs de NHE-1 ; des inhibiteurs de glycogène-phosphorylase ; des inhibiteurs de réabsorption de sérotonine sélectifs ; des agonistes de GABA ; des agents antihypertenseurs ; des inhibiteurs de 3-hydroxy-3-méthylglutaryl-coenzyme-A-réductase ; des inhibiteurs de phosphodiestérase-5 ; et des agents abaissant les taux de glucose.
MA27314A 2001-03-30 2003-09-17 Pyridazinones servant d'inhibiteurs d'aldose-reductase. MA27003A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
MA27003A1 true MA27003A1 (fr) 2004-12-20

Family

ID=23071435

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27314A MA27003A1 (fr) 2001-03-30 2003-09-17 Pyridazinones servant d'inhibiteurs d'aldose-reductase.

Country Status (44)

Country Link
US (2) US6579879B2 (fr)
EP (3) EP1373259B1 (fr)
JP (1) JP2004528319A (fr)
KR (1) KR100586138B1 (fr)
CN (1) CN1215067C (fr)
AP (1) AP2002002461A0 (fr)
AR (1) AR035798A1 (fr)
AT (3) ATE286049T1 (fr)
AU (1) AU2002226634B2 (fr)
BG (1) BG108179A (fr)
BR (1) BR0208571A (fr)
CA (1) CA2442476A1 (fr)
CZ (1) CZ20032563A3 (fr)
DE (3) DE60217930T2 (fr)
DK (2) DK1373259T3 (fr)
EA (1) EA006023B1 (fr)
EC (1) ECSP034671A (fr)
EE (1) EE200300470A (fr)
ES (2) ES2274369T3 (fr)
GE (1) GEP20053675B (fr)
HK (1) HK1061678A1 (fr)
HR (1) HRP20030752A2 (fr)
HU (1) HUP0303644A3 (fr)
IL (1) IL156462A0 (fr)
IS (3) IS2205B (fr)
MA (1) MA27003A1 (fr)
MX (1) MXPA03008850A (fr)
MY (1) MY134304A (fr)
NO (1) NO20034345L (fr)
NZ (1) NZ528406A (fr)
OA (1) OA12453A (fr)
PA (1) PA8541801A1 (fr)
PE (1) PE20030007A1 (fr)
PL (1) PL365294A1 (fr)
PT (2) PT1373259E (fr)
SI (1) SI1373259T1 (fr)
SK (1) SK11852003A3 (fr)
TN (1) TNSN02037A1 (fr)
TW (1) TWI245762B (fr)
UA (1) UA73236C2 (fr)
UY (1) UY27237A1 (fr)
WO (1) WO2002079198A1 (fr)
YU (1) YU71403A (fr)
ZA (1) ZA200304671B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
PL371258A1 (en) 2002-01-09 2005-06-13 Pfizer Products Inc. Process and intermediates for pyridazinone antidiabetic agents
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1750862B1 (fr) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (fr) * 2004-06-30 2006-03-16 Whitehead Institute For Biomedical Research Procedes pour analyse de site haut rendement au niveau du genome
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
ME00535B (me) 2006-06-27 2011-10-10 Takeda Pharmaceuticals Co Fuzionisana ciklična jedinjenja
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2116618A1 (fr) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnostic et traitement de la maladie de Kawasaki
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
TWI464147B (zh) * 2011-09-15 2014-12-11 Univ Taipei Medical 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
EP3283074A4 (fr) * 2015-04-14 2018-12-05 Case Western Reserve University Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
CN115160339B (zh) 2016-06-21 2024-05-14 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其使用方法
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
WO2018145080A1 (fr) 2017-02-06 2018-08-09 Case Western Reserve University Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
JP2022534426A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー， インコーポレイテッド Ｔｅａｄ阻害剤およびその使用
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
WO2022120353A1 (fr) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1992009594A1 (fr) * 1990-11-30 1992-06-11 Tsumura & Co. Derive de benzopyrone et inhibiteur de reductase d'aldose contenant ce derive en tant qu'ingredient actif
BR9205810A (pt) 1991-03-28 1994-06-28 Pfizer Acidos piridazinona acéticos
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU735729B2 (en) * 1997-09-24 2001-07-12 Orion Corporation Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
AU2002226634B2 (en) * 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
AU2002236131B2 (en) * 2001-04-30 2005-04-14 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
PL371258A1 (en) * 2002-01-09 2005-06-13 Pfizer Products Inc. Process and intermediates for pyridazinone antidiabetic agents

Also Published As

Publication number Publication date
DK1373259T3 (da) 2005-03-29
JP2004528319A (ja) 2004-09-16
DE60202452T2 (de) 2006-02-09
ZA200304671B (en) 2004-06-25
EP1491541B1 (fr) 2007-01-24
DE60202452D1 (de) 2005-02-03
PT1491540E (pt) 2007-01-31
KR20030088484A (ko) 2003-11-19
TNSN02037A1 (fr) 2005-12-23
PE20030007A1 (es) 2003-01-28
CA2442476A1 (fr) 2002-10-10
NZ528406A (en) 2004-03-26
IS2205B (is) 2007-02-15
OA12453A (en) 2006-05-24
HUP0303644A2 (hu) 2004-03-01
EE200300470A (et) 2004-02-16
TWI245762B (en) 2005-12-21
NO20034345D0 (no) 2003-09-29
WO2002079198A1 (fr) 2002-10-10
SK11852003A3 (sk) 2004-07-07
CZ20032563A3 (cs) 2004-05-12
DE60216823D1 (de) 2007-01-25
BR0208571A (pt) 2004-03-23
MXPA03008850A (es) 2003-12-04
DE60217930T2 (de) 2007-10-18
NO20034345L (no) 2003-09-29
ES2274369T3 (es) 2007-05-16
ES2231681T3 (es) 2005-05-16
AR035798A1 (es) 2004-07-14
DE60216823T2 (de) 2007-10-04
GEP20053675B (en) 2005-11-25
SI1373259T1 (en) 2005-04-30
CN1215067C (zh) 2005-08-17
AP2002002461A0 (en) 2002-06-30
US20020143017A1 (en) 2002-10-03
HUP0303644A3 (en) 2008-06-30
KR100586138B1 (ko) 2006-06-07
PL365294A1 (en) 2004-12-27
IL156462A0 (en) 2004-01-04
DK1491540T3 (da) 2007-03-26
EP1491541A1 (fr) 2004-12-29
AU2002226634B2 (en) 2007-01-25
EP1491540B1 (fr) 2006-12-13
ATE348100T1 (de) 2007-01-15
UY27237A1 (es) 2002-12-31
MY134304A (en) 2007-12-31
HRP20030752A2 (en) 2005-06-30
US20030162784A1 (en) 2003-08-28
ECSP034671A (es) 2003-08-29
HK1061678A1 (en) 2004-09-30
UA73236C2 (en) 2005-06-15
DE60217930D1 (de) 2007-03-15
IS8251A (is) 2006-01-23
EP1491540A1 (fr) 2004-12-29
PA8541801A1 (es) 2002-10-28
US6849629B2 (en) 2005-02-01
IS6845A (is) 2003-06-16
CN1500087A (zh) 2004-05-26
DE60202452C5 (de) 2006-11-23
ATE352551T1 (de) 2007-02-15
EP1373259B1 (fr) 2004-12-29
IS8250A (is) 2006-01-23
US6579879B2 (en) 2003-06-17
EP1373259A1 (fr) 2004-01-02
BG108179A (en) 2004-09-30
EA200300673A1 (ru) 2003-12-25
YU71403A (sh) 2006-05-25
PT1373259E (pt) 2005-03-31
EA006023B1 (ru) 2005-08-25
ATE286049T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
MA27003A1 (fr) Pyridazinones servant d'inhibiteurs d'aldose-reductase.
Zicha et al. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: the possible role of superoxide anions
MA26965A1 (fr) Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
Jaimes et al. Nicotine: the link between cigarette smoking and the progression of renal injury?
MA27154A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
TNSN06038A1 (fr) Derives d'indazole 3,5-disubstitues, compositions pharmaceutiques, et methodes de mediation ou d'inhibition de la proliferation cellulaire
MA26954A1 (fr) ALPHA-ARYLETHANOLAMINES ET LEUR UTILISATION COMME AGONISTES DES RECEPTEURS BeTA3-ADRENERGIQUES
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
MA26873A1 (fr) Derives de purine
Ganz Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
WO2006028957A8 (fr) Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
TN2010000073A1 (fr) Compositon pharmaceutique contenant un derive de benzene substitue par glucopyranosyle
Fujita et al. CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1
DE69331988D1 (de) Indol derivate als 5-ht1 agoniste
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
Pettinati Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence
Doki et al. Effects of CYP2D6 genotypes on age‐related change of flecainide metabolism: involvement of CYP1A2‐mediated metabolism
TNSN06313A1 (fr) Derive de pyrazole cristallin